Pliant Therapeutics Taps Veteran Oncologist Dr. David Raben as CMO Ahead of 2027 Readouts

SOUTH SAN FRANCISCO, Calif. – September 30, 2026 -- In a strategic move signaling a critical phase of clinical execution, Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced the appointment of Dr. David Raben as its new Chief Medical Officer. The leadership transition, effective today, arrives as the clinical-stage biotechnology company accelerates the development of its lead oncology asset, PLN-101095, toward pivotal trial readouts anticipated in 2027.

Pliant, historically recognized for its integrin-based therapeutic platforms, has recently sharpened its focus entirely on targeted immuno-oncology. The acquisition of Dr. Raben—a veteran with over three decades of experience spanning academic translational research and biopharmaceutical executive leadership—underscores the company's commitment to navigating the complex regulatory and developmental pathways of the oncology sector.

A Calculated Move for Clinical Acceleration

Dr. Raben joins Pliant after a highly relevant tenure as Chief Medical Officer at Bicara Therapeutics. During his time there, he oversaw the clinical development of ficerafusp alfa (BCA101), a first-in-class bifunctional antibody platform. His move to Pliant brings a directly applicable playbook, particularly given that Bicara’s lead asset also targets the TGF-β pathway to combat solid tumors.

Prior to his C-suite role at Bicara, Dr. Raben held significant leadership positions at two of the industry's heaviest hitters. As Vice President of Global Product Development and Product General Manager for Oncology at Amgen, he directed the strategy and clinical execution for the anti-DLL3 program in neuroendocrine cancers. Before that, he served as Vice President and Franchise Leader for Oncology Clinical Development at Genentech, overseeing late-stage precision medicine and immunotherapy programs across head and neck, skin, and thoracic cancers.

“David’s deep expertise in advancing innovative and targeted oncology therapies, alongside a proven track record of leading programs from early development through regulatory approval, will be important as we advance PLN-101095,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant.

To secure this caliber of executive talent, Pliant utilized an inducement grant under Nasdaq Listing Rule 5635(c)(4), awarding Dr. Raben 575,000 non-statutory stock options. The options, matching the closing price on his September 30 start date, vest over a four-year period—a standard but crucial mechanism designed to align executive incentives with long-term shareholder value and the successful execution of upcoming clinical milestones.

Overcoming Checkpoint Resistance

The central scientific challenge Dr. Raben has been hired to tackle is immune checkpoint inhibitor (ICI) resistance. While ICIs like pembrolizumab have revolutionized cancer care, a significant portion of patients either do not respond initially or develop resistance over time. A primary culprit in this resistance is the transforming growth factor-β (TGF-β) pathway, which creates an immunosuppressive fortress around the tumor microenvironment.

TGF-β is secreted in a latent, inactive form that must be physically unlocked by specific integrins on the surface of cells. Pliant’s lead program, PLN-101095, offers a novel approach to dismantling this fortress. As an oral, small molecule, dual-selective inhibitor of αvβ8 and αvβ1 integrins, the drug is designed to block this physical unlocking mechanism, preventing the activation of TGF-β before it can suppress the immune system. By halting this localized immunosuppression, the therapy aims to reinvigorate the body's T-cell response and re-sensitize the tumor to checkpoint inhibitors.

The commercial stakes are substantial, given that non-small cell lung cancer (NSCLC) and clear cell renal cell carcinoma (ccRCC) represent massive patient populations with high unmet needs once standard immunotherapies fail. The asset is currently being evaluated in FORTIFY, a Phase 1b indication expansion trial targeting patients with NSCLC, ccRCC, and tumors with high tumor mutational burden.

Interim data from the Phase 1a dose-escalation portion, released in late 2025, demonstrated a 60% disease control rate and confirmed clinical responses in heavily pretreated patients when combined with pembrolizumab. Recognizing this potential, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the combination therapy in August 2026, a regulatory tailwind that Dr. Raben is now uniquely positioned to leverage as the company drives toward its 2027 milestones.

The Academic to C-Suite Pipeline

Dr. Raben’s appointment also highlights a broader industry trend: the migration of elite academic translational researchers into biotech C-suites. Before entering the corporate sector, Dr. Raben spent more than 20 years as a professor at the University of Colorado Cancer Center.

His academic research was not merely theoretical; it was hyper-focused on the exact biological mechanisms Pliant is now trying to drug. Specializing in locally advanced head, neck, and lung cancers, his laboratory and clinical work explored the intersections of EGFR signaling, DNA damage repair, checkpoint inhibition, and, crucially, TGF-β. This deep, mechanistic understanding of the tumor microenvironment provides Pliant with a Chief Medical Officer who possesses both the operational acumen to run global trials and the scientific fluency to interpret complex biomarker data.

Furthermore, his legacy of collaborative leadership—having served for over 15 years on the NRG Oncology Head and Neck Cancer Steering Committee and co-founding the NRG Radiation Developmental Therapeutics Committee—ensures Pliant has a well-connected advocate within the broader oncology research community.

Financial Runway and Strategic Refocusing

The timing of this appointment is critical from a corporate strategy perspective. Pliant is emerging from a period of significant restructuring. Following the 2025 discontinuation of its idiopathic pulmonary fibrosis (IPF) program, bexotegrast, due to an unfavorable risk-benefit profile, the company swiftly reprioritized its capital and operational focus entirely toward its oncology pipeline.

This strategic pivot has yielded a much leaner, highly focused organization. According to its Q2 2026 financial reports, Pliant successfully reduced its research and development expenses by nearly half, dropping from $32.2 million to $16.7 million year-over-year. General and administrative expenses saw a similar contraction.

More importantly, the company reported holding $159.6 million in cash, cash equivalents, restricted cash, and short-term investments as of June 30, 2026. Management has indicated that this capital reserve provides a financial runway extending well beyond the next 12 months. Additionally, Pliant maintains an at-the-market (ATM) facility allowing for the issuance of up to $50.0 million of common stock, though no sales have been executed to date, preserving shareholder value.

This financial stability is a vital metric for investors, as it confirms Pliant is sufficiently capitalized to carry the FORTIFY trial through to its highly anticipated 2027 interim data readouts without an immediate, dilutive need to tap the equity markets. With a fortified balance sheet, a Fast Track designated lead asset, and a newly appointed Chief Medical Officer whose resume bridges the gap between academic tumor biology and late-stage pharma commercialization, Pliant Therapeutics is positioning itself to be a formidable player in the next generation of targeted immuno-oncology.